Christopher J. Senner
Director; EVP and CFO · 6 filings · Latest: Jun 11, 2026
EXELIXIS, INC.
Quince Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
EXEL | Christopher J. Senner | EVP and CFO | May 18, 2026 | Sale | $50.00 | 34,901 | $1.7M | 952,317 | |
EXEL | CHRISTOPHER J SENNER | — | May 18, 2026 | Proposed Sale | $50.00 | 34,901 | $1.7M | — | |
EXEL | Christopher J. Senner | EVP and CFO | Feb 17, 2026 | Sale | $43.67 | 30,617 | $1.3M | 976,092 | |
EXEL | Christopher J. Senner | EVP and CFO | Feb 13, 2026 | Sale | $43.00 | 34,278 | $1.5M | 1,042,579 | |
EXEL | CHRISTOPHER J SENNER | — | Feb 17, 2026 | Proposed Sale | $43.67 | 30,617 | $1.3M | — | |
EXEL | CHRISTOPHER J SENNER | — | Feb 13, 2026 | Proposed Sale | $43.00 | 34,278 | $1.5M | — | |
EXEL | CHRISTOPHER J SENNER | — | May 16, 2025 | Proposed Sale | $46.00 | 100,000 | $4.6M | — | |
EXEL | Senner Christopher J. | — | Feb 24, 2025 | Proposed Sale | $36.14 | 29,314 | $1.1M | — |